Recursion Pharmaceuticals is trading 4.6% down at $3.87 as U.S. equities weaken. - The Nasdaq Composite is down 1.00%, and the S&P 500 is down 0.55%. - Brent crude rose approximately 1.3% to $100.55, while the 10-year Treasury yield reached 4.99%, pressuring growth and biotech valuations. - Recent company-specific attention centered on the September 21 Tempus AI licensing deal, but no newer catalyst directly explains the September 23 decline.